Durability of Response to SARS-CoV-2 BNT162b2 Vaccination in Patients on Active Anticancer Treatment
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358809/
This cohort study examines the durability of immune response from BNT162b2 vaccination for severe acute respiratory syndrome coronavirus 2 in patients with cancer vs healthy controls.
Herein, we describe the anti-S response in the patients with cancer vs the controls approximately 4 months after the second vaccine dose.
Another Year Of Close Collaboration Authorized In Australia
Source : 'Generics Bulletin'
Collaborative activities between the Australian Generic and Biosimilar Medicines Association and brand industry body Medicines Australia, aimed at mitigating shortages against the backdrop of the COVID-19 pandemic, can continue for...
Guntern Takes Lead At Medicines For Europe
Source : 'Generics Bulletin'
European off-patent industry association Medicines for Europe has announced the appointment of Sandoz International GmbH’s head of Europe, Rebecca Guntern, as the body’s president for an interim term...
